Are antibodies to the capsular polysaccharide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology?
As polysialic acid (PSA), the capsule of Group B meningococcus (GBM) and Escherichia coli K1, is a component of mammalian glycopeptides, there is concern that vaccines against PSA could induce immunopathology. Purified PSA is not immunogenic; however, as a component of bacteria or bound to proteins,...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2006-01, Vol.24 (3), p.221-228 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 228 |
|---|---|
| container_issue | 3 |
| container_start_page | 221 |
| container_title | Vaccine |
| container_volume | 24 |
| creator | Stein, Daniel M. Robbins, John Miller, Mark A. Lin, Feng-Ying C. Schneerson, Rachel |
| description | As polysialic acid (PSA), the capsule of Group B meningococcus (GBM) and
Escherichia coli K1, is a component of mammalian glycopeptides, there is concern that vaccines against PSA could induce immunopathology. Purified PSA is not immunogenic; however, as a component of bacteria or bound to proteins, it induces protective antibodies. In this review, we did not unearth data indicating an association of IgG anti-PSA with immunopathology in experimental animals or humans. We found no increased incidence of autoimmunity from GBM infections in our review of the natural history/sequellae of
Neisseria meningitis infections. Accordingly, we propose that clinical trials of PSA conjugate vaccines, be considered. |
| doi_str_mv | 10.1016/j.vaccine.2005.07.084 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67577140</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X05007681</els_id><sourcerecordid>20447681</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-66f21fb8d2b346e74dd7dd2ad1cab7bb251f16ec0e4f85591831ad18b850cf03</originalsourceid><addsrcrecordid>eNqF0c1u1DAQB_AIgehSeASQL3BLsB3Hdk9VW5UPUcGlB26WY082s0riYCdF-wY8Nq42Uo89-eDfzHj8L4r3jFaMMvn5UD1Y53CCilPaVFRVVIsXxY5pVZe8YfplsaNcilIw-vuseJPSgWZYs4vXxRmTjDeai13x7yoCsdOCbfAIiSyBLD0QZ-e0DjaSOQzHlAf1NqIHEjryEzAliGjJCBNOe1zQYyL7GNaZXOdentwm12fh-oxcGJD8YMSmFBzaBTz5i0tPcBzXKcx26cMQ9sfLt8Wrzg4J3m3neXH_5fb-5lt59-vr95uru9IJLpZSyo6zrtWet7WQoIT3yntuPXO2VW2bN--YBEdBdLppLpiuWb7UrW6o62h9Xnw6tZ1j-LNCWsyIycEw2AnCmoxUjVJMPA85FUJJzTJsTtDFkFKEzswRRxuPhlHzGJU5mC0q8xiVocrkqHLdh23A2o7gn6q2bDL4uAGbnB26aCeH6ckpQTWnMrvLk4P8bQ8I0SSHMDnwGMEtxgd85in_AUyot1I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20447681</pqid></control><display><type>article</type><title>Are antibodies to the capsular polysaccharide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology?</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Stein, Daniel M. ; Robbins, John ; Miller, Mark A. ; Lin, Feng-Ying C. ; Schneerson, Rachel</creator><creatorcontrib>Stein, Daniel M. ; Robbins, John ; Miller, Mark A. ; Lin, Feng-Ying C. ; Schneerson, Rachel</creatorcontrib><description>As polysialic acid (PSA), the capsule of Group B meningococcus (GBM) and
Escherichia coli K1, is a component of mammalian glycopeptides, there is concern that vaccines against PSA could induce immunopathology. Purified PSA is not immunogenic; however, as a component of bacteria or bound to proteins, it induces protective antibodies. In this review, we did not unearth data indicating an association of IgG anti-PSA with immunopathology in experimental animals or humans. We found no increased incidence of autoimmunity from GBM infections in our review of the natural history/sequellae of
Neisseria meningitis infections. Accordingly, we propose that clinical trials of PSA conjugate vaccines, be considered.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2005.07.084</identifier><identifier>PMID: 16125824</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Animals ; Antibodies, Bacterial - immunology ; Antibodies, Monoclonal - immunology ; Antibodies, Monoclonal - pharmacology ; Antigens, Bacterial - immunology ; Applied microbiology ; Autoimmune Diseases - drug therapy ; Autoimmune Diseases - immunology ; Autoimmunity ; Bacterial Capsules ; Bacteriology ; Biological and medical sciences ; Escherichia coli ; Fundamental and applied biological sciences. Psychology ; Humans ; Lipopolysaccharides - immunology ; Meningococcal Infections - immunology ; Microbiology ; Miscellaneous ; Neisseria meningitidis ; Neisseria meningitidis, Serogroup B - immunology ; Polysaccharides, Bacterial - immunology ; Polysialic acid (poly α(2 → 8) N-acetylneuraminic acid) ; Sialic Acids - immunology ; Vaccine ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><ispartof>Vaccine, 2006-01, Vol.24 (3), p.221-228</ispartof><rights>2005</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-66f21fb8d2b346e74dd7dd2ad1cab7bb251f16ec0e4f85591831ad18b850cf03</citedby><cites>FETCH-LOGICAL-c424t-66f21fb8d2b346e74dd7dd2ad1cab7bb251f16ec0e4f85591831ad18b850cf03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.vaccine.2005.07.084$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3549,27923,27924,45994,64386</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17408206$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16125824$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stein, Daniel M.</creatorcontrib><creatorcontrib>Robbins, John</creatorcontrib><creatorcontrib>Miller, Mark A.</creatorcontrib><creatorcontrib>Lin, Feng-Ying C.</creatorcontrib><creatorcontrib>Schneerson, Rachel</creatorcontrib><title>Are antibodies to the capsular polysaccharide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology?</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>As polysialic acid (PSA), the capsule of Group B meningococcus (GBM) and
Escherichia coli K1, is a component of mammalian glycopeptides, there is concern that vaccines against PSA could induce immunopathology. Purified PSA is not immunogenic; however, as a component of bacteria or bound to proteins, it induces protective antibodies. In this review, we did not unearth data indicating an association of IgG anti-PSA with immunopathology in experimental animals or humans. We found no increased incidence of autoimmunity from GBM infections in our review of the natural history/sequellae of
Neisseria meningitis infections. Accordingly, we propose that clinical trials of PSA conjugate vaccines, be considered.</description><subject>Animals</subject><subject>Antibodies, Bacterial - immunology</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antigens, Bacterial - immunology</subject><subject>Applied microbiology</subject><subject>Autoimmune Diseases - drug therapy</subject><subject>Autoimmune Diseases - immunology</subject><subject>Autoimmunity</subject><subject>Bacterial Capsules</subject><subject>Bacteriology</subject><subject>Biological and medical sciences</subject><subject>Escherichia coli</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Humans</subject><subject>Lipopolysaccharides - immunology</subject><subject>Meningococcal Infections - immunology</subject><subject>Microbiology</subject><subject>Miscellaneous</subject><subject>Neisseria meningitidis</subject><subject>Neisseria meningitidis, Serogroup B - immunology</subject><subject>Polysaccharides, Bacterial - immunology</subject><subject>Polysialic acid (poly α(2 → 8) N-acetylneuraminic acid)</subject><subject>Sialic Acids - immunology</subject><subject>Vaccine</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0c1u1DAQB_AIgehSeASQL3BLsB3Hdk9VW5UPUcGlB26WY082s0riYCdF-wY8Nq42Uo89-eDfzHj8L4r3jFaMMvn5UD1Y53CCilPaVFRVVIsXxY5pVZe8YfplsaNcilIw-vuseJPSgWZYs4vXxRmTjDeai13x7yoCsdOCbfAIiSyBLD0QZ-e0DjaSOQzHlAf1NqIHEjryEzAliGjJCBNOe1zQYyL7GNaZXOdentwm12fh-oxcGJD8YMSmFBzaBTz5i0tPcBzXKcx26cMQ9sfLt8Wrzg4J3m3neXH_5fb-5lt59-vr95uru9IJLpZSyo6zrtWet7WQoIT3yntuPXO2VW2bN--YBEdBdLppLpiuWb7UrW6o62h9Xnw6tZ1j-LNCWsyIycEw2AnCmoxUjVJMPA85FUJJzTJsTtDFkFKEzswRRxuPhlHzGJU5mC0q8xiVocrkqHLdh23A2o7gn6q2bDL4uAGbnB26aCeH6ckpQTWnMrvLk4P8bQ8I0SSHMDnwGMEtxgd85in_AUyot1I</recordid><startdate>20060116</startdate><enddate>20060116</enddate><creator>Stein, Daniel M.</creator><creator>Robbins, John</creator><creator>Miller, Mark A.</creator><creator>Lin, Feng-Ying C.</creator><creator>Schneerson, Rachel</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T5</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20060116</creationdate><title>Are antibodies to the capsular polysaccharide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology?</title><author>Stein, Daniel M. ; Robbins, John ; Miller, Mark A. ; Lin, Feng-Ying C. ; Schneerson, Rachel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-66f21fb8d2b346e74dd7dd2ad1cab7bb251f16ec0e4f85591831ad18b850cf03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Animals</topic><topic>Antibodies, Bacterial - immunology</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antigens, Bacterial - immunology</topic><topic>Applied microbiology</topic><topic>Autoimmune Diseases - drug therapy</topic><topic>Autoimmune Diseases - immunology</topic><topic>Autoimmunity</topic><topic>Bacterial Capsules</topic><topic>Bacteriology</topic><topic>Biological and medical sciences</topic><topic>Escherichia coli</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Humans</topic><topic>Lipopolysaccharides - immunology</topic><topic>Meningococcal Infections - immunology</topic><topic>Microbiology</topic><topic>Miscellaneous</topic><topic>Neisseria meningitidis</topic><topic>Neisseria meningitidis, Serogroup B - immunology</topic><topic>Polysaccharides, Bacterial - immunology</topic><topic>Polysialic acid (poly α(2 → 8) N-acetylneuraminic acid)</topic><topic>Sialic Acids - immunology</topic><topic>Vaccine</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stein, Daniel M.</creatorcontrib><creatorcontrib>Robbins, John</creatorcontrib><creatorcontrib>Miller, Mark A.</creatorcontrib><creatorcontrib>Lin, Feng-Ying C.</creatorcontrib><creatorcontrib>Schneerson, Rachel</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stein, Daniel M.</au><au>Robbins, John</au><au>Miller, Mark A.</au><au>Lin, Feng-Ying C.</au><au>Schneerson, Rachel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Are antibodies to the capsular polysaccharide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology?</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2006-01-16</date><risdate>2006</risdate><volume>24</volume><issue>3</issue><spage>221</spage><epage>228</epage><pages>221-228</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>As polysialic acid (PSA), the capsule of Group B meningococcus (GBM) and
Escherichia coli K1, is a component of mammalian glycopeptides, there is concern that vaccines against PSA could induce immunopathology. Purified PSA is not immunogenic; however, as a component of bacteria or bound to proteins, it induces protective antibodies. In this review, we did not unearth data indicating an association of IgG anti-PSA with immunopathology in experimental animals or humans. We found no increased incidence of autoimmunity from GBM infections in our review of the natural history/sequellae of
Neisseria meningitis infections. Accordingly, we propose that clinical trials of PSA conjugate vaccines, be considered.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>16125824</pmid><doi>10.1016/j.vaccine.2005.07.084</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2006-01, Vol.24 (3), p.221-228 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67577140 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
| subjects | Animals Antibodies, Bacterial - immunology Antibodies, Monoclonal - immunology Antibodies, Monoclonal - pharmacology Antigens, Bacterial - immunology Applied microbiology Autoimmune Diseases - drug therapy Autoimmune Diseases - immunology Autoimmunity Bacterial Capsules Bacteriology Biological and medical sciences Escherichia coli Fundamental and applied biological sciences. Psychology Humans Lipopolysaccharides - immunology Meningococcal Infections - immunology Microbiology Miscellaneous Neisseria meningitidis Neisseria meningitidis, Serogroup B - immunology Polysaccharides, Bacterial - immunology Polysialic acid (poly α(2 → 8) N-acetylneuraminic acid) Sialic Acids - immunology Vaccine Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) |
| title | Are antibodies to the capsular polysaccharide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T12%3A19%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Are%20antibodies%20to%20the%20capsular%20polysaccharide%20of%20Neisseria%20meningitidis%20group%20B%20and%20Escherichia%20coli%20K1%20associated%20with%20immunopathology?&rft.jtitle=Vaccine&rft.au=Stein,%20Daniel%20M.&rft.date=2006-01-16&rft.volume=24&rft.issue=3&rft.spage=221&rft.epage=228&rft.pages=221-228&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2005.07.084&rft_dat=%3Cproquest_cross%3E20447681%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20447681&rft_id=info:pmid/16125824&rft_els_id=S0264410X05007681&rfr_iscdi=true |